Regen BioPharma, Inc. (RGBP)

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

• Founded in 2012 as a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.
• Fully reporting and trades publicly under the symbol: RGBP
• Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing
• Currently 2 Investigational New Drug applications (IND) filed with the FDA
• Three products in preclinical development based on the newly discovered cancer stem cell gene target

Areas of interest to the Company include:

  • Hematopoiesis (Blood formation)
  • Breast Cancer
  • Liver Cancer
  • Leukemia
  • Myelodysplastic Syndrome
  • Aplastic Anemia

Company Website:

www.regenbiopharmainc.com

Contact Info:

REGEN BIOPHARMA, INC.
4700 Spring Street, Suite 304
La Mesa, CA 91942
U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328



Key Personnel:

Management Team | Regen BioPharma, Inc.


David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

 

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 31 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.

 

 

 


Harry Lander, PhD, MBA
President and Chief Scientific Officer

Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research.  He has a deep knowledge of operations and research administration.  Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills.  Highly effective at strategic planning, problem solving and operational excellence.  Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth.

Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).


Todd S. Caven
Chief Financial Officer

Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States.

In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum).

​Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

 


Xiaojing Ma, Ph.D.
Senior Research Consultant

Dr. Ma is a Professor of Microbiology and Immunology at Weill Cornell Medical College.  With over 100 scientific papers published and large research laboratory at a premier university, Dr. Ma brings extensive expertise to Regen as we develop our NR2F6 small molecules.​Dr. Ma has been studying cytokines, particularly the IL-10 and IL-12 family of interleukins, for more than 20 years in many aspects of their regulation and immunobiology in various inflammatory autoimmune and tumor-immune models.Dr. Ma’s group first identified a novel function of the Crohn’s disease-associated NOD2 mutation and uncovered the mechanisms by which IL-12 induces strong cell-mediated immune responses against various malignancies.  He was also the first to identify a novel, non-chemokine activity of CCL5 in the generation and function of myeloid-derived suppressor cells and tumor-associated macrophages in the regulation of immune responses against breast cancer/mammary tumor.

Scientific Advisory Board | Regen BioPharma, Inc.


Lorraine J. Gudas, PhD

Dr. Gudas is Chairman and Revlon Pharmaceutical Professor of Pharmacology and Toxicology of the Department of Pharmacology at Weill Cornell Medical College and is recognized as one of the world experts on nuclear receptors.Dr. Gudsas is a member of the American Society for Pharmacology and Experimental Therapeutics and a Fellow of the American Association for the Advancement of Science. She has served a term as an elected member of the Board of Directors of the American Association of Cancer Research and as chair of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Disorders as well as the Board of Scientific Counselors of the National Heart, Lung and Blood Institute. She has served as a member of the external advisory boards of three Cancer Centers: The Vermont Cancer Center, The Lineberger Cancer Center of U.N.C. Chapel Hill, and the University of Maryland Greenebaum Cancer Center. In 1999 she received the 2nd Annual “Women in Cancer Research” award from the American Association of Cancer Research. She is on the Editorial Boards of a number of journals, including Molecular Cancer Therapeutics, Molecular and Cellular Biology, Molecular Cancer Research and the Journal of Biological Chemistry. She has had a long-standing research interest in retinoids. She and her laboratory members have studied the pharmacology and molecular actions of retinoids with respect to cancer treatment and cancer prevention for over twenty years, during which time her research has been continuously supported by NIH and other agencies. She received the 2013 Future of Health Technology Award for her cancer research.Dr. Gudas will advise Regen on scientific strategies and opportunities across its pipeline, with particular emphasis on the NR2F6 checkpoint inhibitor target.


Ralph Nachman, M.D.

A renown hematologist, is a member of the Institute of Medicine and University Professor and former Chairman of Medicine at NY Presbyterian/Weill Cornell Medical Center.  Dr. Nachman, the Lewis Thomas University Professor and Associate Dean of Clinical Research at Weill Cornell Medical College, is a physician, scientist, educator and administrator. Dr. Nachman has pioneered discoveries in hematology and medical oncology that have furthered the development of new clinical solutions to blood and vascular disorders.

Dr. Nachman has spearheaded multiple endeavors in biomedical research, clinical programs, educational curricula, residency training, fundraising, and quality assurance. His discoveries in vascular biology, and the establishment of the Specialized Center of Research (SCOR) in Thrombosis (National Institutes of Health) at New York-Cornell, led to his performing the first culture of human endothelial cells. This achievement initiated a modern explosion of knowledge in vascular biology. He has published numerous articles in the field of hematology and has lectured around the world. His honors include, The Stratton Award from the American Society of Hematology and the Robert Williams, MD Distinguished Chair of Medicine Award from the Association of Professors of Medicine. He is a member of the Institute of Medicine of the National Academy of Sciences.


Helen Sabzevari, Ph.D.

Is a key leader in developing immunotherapies, was senior vice president and head of immuno-oncology, global research and early development at EMD Serono (Merck Serono).   Dr, Sabzevari is the co-founder of Compass Therapeutics, which is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. Novel scientific insights are validated and explored deeply inside our labs before Compass pursues the best proprietary combinations of therapeutics into human clinical trials. ​


Stefano Bertuzzi, PhD, MPH

Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executive Director and CEO of the American Society for Microbiology, effective January 4, 2016.  Before leading the American Society for Cell Biology, Dr. Bertuzzi was a senior scientific executive at the National Institutes of Health where he served as Director of the Office of Science Policy, Planning, and Communications, and as a science policy advisor to the NIH Director.  Dr. Bertuzzi received his Ph.D. in Molecular Biotechnology from Milan, Italy and his Master’s in Public Health from the Bloomberg School of Public Health at the Johns Hopkins University in Baltimore with a specialization in health policy.


David James Graham White, MD, PhD

Emeritus Professor Schulic School of Medicine, Novartis Global Research Management Board. Pioneered organ transplantation by introducing cyclosporine into clinical practice with Professor Sir Roy Calne. Published over 300 peer reviewed papers.


David A. Suhy, PhD

Senior VP Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.


Weiping Min, MD, PhD

Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejection. Inventor of dCellVax, over 5 million dollars in grant funding.


Amit Patel, MD, MSc

Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah. First to administer stem cells into human heart, currently investigator on over 17 FDA clinical trials.


Santosh Kesari, MD, PhD

Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center, and the Translational Neuro-Oncology Laboratories at Moores Cancer Center. Professor of Neurosciences at the UCSD School of Medicine.


Rohit Duggal, PhD

17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer stem cell group. He has led development of drugs which entered clinical trials, including development of Filibuvir. Granted the prestigious Pfizer Achievement Award. At Genelux Corp he established the cancer stem cell program.


Boris Minev, MD

Director of Immunotherapy and Translational Oncology at Genelux Corporation. Dr. Minev previously worked as the Principal Investigator at the Laboratory of Tumor Immunology and Immunotherapy at the Moores UCSD Cancer Center.


Hinrich Gronemeyer, PhD

Research Director at the IGBMC in Strasbourg-Illkirch and Research Director (Class ‘Exceptional’) of the French National Institute of Health and Medical Research (INSERM). His 189 publications received an average citation of 83.34. Hinrich Gronemeyer contributed to pioneering work on nuclear receptors and their therapeutic intervention by design of small molecule ligands.


William S. Blaner, PhD

Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of retinoids. He is an author on more than 200 publications.


Louise Purton, PhD

Associate Professor at the St. Vincent’s Institute of Medical Research at the University of Melbourne, Co-Head of the Stem Cell Regulation Unit and Associate Director at the Institute. Her laboratory is focused on researching how retinoic acid affects stem cells in the bone marrow in healthy or leukemic states.


Jonathan Baell, PhD

Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature).  He has 40 granted patents listed in www.lens.org.

He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.

For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.

/**/
Subscribe now!